Molbio Diagnostics Ltd (MOLBIO)
🎯 Key Takeaways
- Molbio Diagnostics Ltd appears to be in a mature, low-growth phase with minimal operational activity and no significant strategic developments recently. The company maintains a conservative capital structure with a debt-to-equity ratio of 0.
- Revenue declined 27.2% QoQ to ₹408 in Q1FY27.
- ⚠️ Persistent lack of revenue or growth indicators raises concerns about business viability.
📖 The Story
Molbio Diagnostics Ltd appears to be in a mature, low-growth phase with minimal operational activity and no significant strategic developments recently. The company maintains a conservative capital structure with a debt-to-equity ratio of 0.35 and negligible net debt, but shows limited reinvestment or expansion. There is no evidence of revenue growth or new product launches in the latest filings.
📰 What's Happening
The most recent filing from August 27, 2026, documents a board meeting that lasted 12 minutes and involved the reappointment of Darshan Raghunath Karekar as Compliance Officer — a role he already held. This action, while compliant with SEBI norms, adds no new strategic or operational dimension. No new orders, expansions, or capital projects were disclosed in the filing.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Revenue | 100 | 561 | 408 |
| Operating Profit | -28 | 139 | 84 |
| OPM % | -27.7% | 24.8% | 20.4% |
| Net Profit | -24 | 96 | 53 |
| EPS | ₹-2.10 | ₹8.05 | ₹5.21 |
The company generated ₹50 lakh in operating cash flow in March 2026, but used ₹93 lakh in investing activities and generated ₹276 lakh in financing cash flow, resulting in a net cash increase of ₹233 lakh. The modest operating cash flow suggests limited revenue generation or margin compression, with no indication from management commentary of scaling or efficiency improvements.
🔮 Management Outlook & What's Next
There is no forward-looking guidance or strategic outlook provided in the latest filing. Management has not articulated any growth targets, product pipelines, or market expansion plans in recent disclosures.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Equity Capital | 11 |
| Reserves | 1,158 |
| Borrowings | 413 |
| Total Liabilities | 2,148 |
| Fixed Assets | 536 |
| Investments | 6 |
| Total Assets | 2,148 |
The balance sheet as of March 2026 shows total assets of ₹2,148 lakh, with equity at ₹11 lakh and reserves at ₹1,158 lakh. Borrowings of ₹413 lakh represent a small portion of capital structure, indicating minimal leverage and a conservative financial posture with no aggressive investment or deleveraging activity.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +50 |
| Investing | -93 |
| Financing | +276 |
| Net Cash Flow | +233 |
⚖️ Peer Comparison — Healthcare
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| APOLLOHOSP | 1.27 L Cr | 60.9 | 22.1% | 22.9% | 0.60 |
| MAXHEALTH | 1.01 L Cr | 69.2 | 14.4% | 13.6% | 0.27 |
| MANIPALHOS | 94,201 | — | — | — | 1.25 |
| FORTIS | 66,987 | 63.9 | 13.3% | 10.8% | 0.29 |
| ASTERDM | 66,504 | 123.5 | 12.9% | 8.6% | 0.17 |
| MEDANTA | 38,921 | 69.9 | 21.9% | 16.3% | 0.10 |
| NH | 38,161 | 46.5 | 13.7% | 18.0% | 1.07 |
| KIMS | 32,292 | 150.8 | 9.7% | 8.7% | 1.44 |
| LALPATHLAB | 32,009 | 46.0 | 29.6% | 21.8% | 0.00 |
| POLYMED | 17,610 | 55.9 | 15.1% | 11.3% | 0.06 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Persistent lack of revenue or growth indicators raises concerns about business viability. 2. Minimal capital expenditure and R&D investment suggest limited innovation or market expansion. 3. Overreliance on reserves and cash balances without clear deployment plans poses capital efficiency risks.
📋 Recent Filings
-
🔴 Financial Results 12 September 2026Molbio Diagnostics reported Q1 FY27 revenue of [amount context mismatch] crores with 25% EBITDA margin and [amount context mismatch] crores PAT, drive...
-
Announcement 9 September 2026Molbio Diagnostics Ltd announced a change to its Corporate Identification Number (CIN) from U33125GA2000PLC002909 to L33125GA2000PLC002909 following i...
-
🔴 Financial Results 8 September 2026Molbio Diagnostics reported Q1 FY27 total income of ₹411.48 crore, up from ₹100.5 crore in Q1 FY26, driven by higher test kit volumes. EBITDA turned p...
-
🔴 Financial Results 8 September 2026Molbio Diagnostics announced that the audio recording of its earnings call for the quarter ended June 30, 2026 is now available on its website, www.mo...
-
🔴 Financial Results 7 September 2026Molbio Diagnostics reported Q1 FY27 total income of ₹411.48 Cr, up from ₹100.47 Cr YoY, with EBITDA turning positive at ₹103.68 Cr versus a ₹14.50 Cr ...
-
🟡 Board Meeting 5 September 2026Molbio Diagnostics announced approval of unaudited standalone and consolidated financial results for Q1 FY2027 ending June 30, 2026, following board a...
-
Announcement 5 September 2026Molbio Diagnostics announced approval of unaudited standalone and consolidated financial results for Q1 FY2026 ending June 30, 2026, following a board...
-
🔴 Announcement 2 September 2026Molbio Diagnostics announced an earnings conference call on September 8, 2026 at 4:00 PM IST to discuss Q1 FY27 results for the quarter ended June 30,...
-
🟡 Board Meeting 1 September 2026Molbio Diagnostics announced a board meeting on September 5, 2026 to approve unaudited financial results for the quarter ended June 30, 2026, with tra...
-
🟡 Board Meeting 27 August 2026Molbio Diagnostics announced the appointment of Darshan Raghunath Karekar as Compliance Officer, a role he already held, making the disclosure unneces...
🧠 Analyst's Read
Molbio Diagnostics currently operates with little visible momentum or strategic direction. Investors should monitor for any future announcements related to product development, revenue growth, or capital allocation that could signal renewed activity.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-13.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when MOLBIO files new disclosures
Track MOLBIO filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track MOLBIO — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd